Article

Key clinical point: In transplant-ineligible patients with untreated mantle cell lymphoma (MCL), bendamustine, rituximab, ibrutinib, and rituximab maintenance (BR-Ibrutinib+R) and bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) should be the preferred immunotherapy regimens for improving progression-free survival (PFS) and overall survival (OS), respectively.

Major finding: BR-Ibrutinib+R resulted in the best PFS, with a surface under the cumulative ranking curve (SUCRA) of 0.89 and probability of being the best treatment (PbBT) of 69% followed by bendamustine, rituximab, and rituximab maintenance (SUCRA 0.76; PbBT 11%). VR-CAP provided the best OS, with a SUCRA of 0.89 and PbBT of 63% followed by bendamustine and rituximab regimen (SUCRA 0.74; PbBT 22%).

Study details: The data come from a network meta-analysis of nine randomized controlled trials involving 2897 transplant-ineligible patients who received first-line chemoimmunotherapy for MCL.

Disclosures: This study was funded by the Achievement Transformation Project and others. The authors declared no conflicts of interest.

Source: Jing C et al. Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials. Cancer Med. 2023 (Jun 1). doi: 10.1002/cam4.6183

Key clinical point: In transplant-ineligible patients with untreated mantle cell lymphoma (MCL), bendamustine, rituximab, ibrutinib, and rituximab maintenance (BR-Ibrutinib+R) and bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) should be the preferred immunotherapy regimens for improving progression-free survival (PFS) and overall survival (OS), respectively.

Major finding: BR-Ibrutinib+R resulted in the best PFS, with a surface under the cumulative ranking curve (SUCRA) of 0.89 and probability of being the best treatment (PbBT) of 69% followed by bendamustine, rituximab, and rituximab maintenance (SUCRA 0.76; PbBT 11%). VR-CAP provided the best OS, with a SUCRA of 0.89 and PbBT of 63% followed by bendamustine and rituximab regimen (SUCRA 0.74; PbBT 22%).

Study details: The data come from a network meta-analysis of nine randomized controlled trials involving 2897 transplant-ineligible patients who received first-line chemoimmunotherapy for MCL.

Disclosures: This study was funded by the Achievement Transformation Project and others. The authors declared no conflicts of interest.

Source: Jing C et al. Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials. Cancer Med. 2023 (Jun 1). doi: 10.1002/cam4.6183

Key clinical point: In transplant-ineligible patients with untreated mantle cell lymphoma (MCL), bendamustine, rituximab, ibrutinib, and rituximab maintenance (BR-Ibrutinib+R) and bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) should be the preferred immunotherapy regimens for improving progression-free survival (PFS) and overall survival (OS), respectively.

Major finding: BR-Ibrutinib+R resulted in the best PFS, with a surface under the cumulative ranking curve (SUCRA) of 0.89 and probability of being the best treatment (PbBT) of 69% followed by bendamustine, rituximab, and rituximab maintenance (SUCRA 0.76; PbBT 11%). VR-CAP provided the best OS, with a SUCRA of 0.89 and PbBT of 63% followed by bendamustine and rituximab regimen (SUCRA 0.74; PbBT 22%).

Study details: The data come from a network meta-analysis of nine randomized controlled trials involving 2897 transplant-ineligible patients who received first-line chemoimmunotherapy for MCL.

Disclosures: This study was funded by the Achievement Transformation Project and others. The authors declared no conflicts of interest.

Source: Jing C et al. Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials. Cancer Med. 2023 (Jun 1). doi: 10.1002/cam4.6183

Key clinical point: The combination of obinutuzumab and bendamustine is a potent treatment option with a manageable safety profile for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Major finding: At a median follow-up of 33.4 months, the median progression-free survival was 26.0 (95% CI 20.3-31.7) months and the median overall survival was not reached. The overall response rate was 78.6%, with 28.6% of patients achieving complete response. The grade ≥3 adverse event (AE) rate was 76.4%, with neutropenia (58.3%), thrombocytopenia (26.4%), and febrile neutropenia (11.1%) being the most common grade ≥3 AE.

Study details: Findings are from the multicenter, phase 2 GABRIELL study that included 72 adult patients with relapsed or refractory CLL who received ≤6 cycles of obinutuzumab plus bendamustine.

Disclosures: This study was funded by Roche Farma SA. Some authors declared serving as advisory board or speaker bureau members with or without honoraria and receiving research support or attendance fees and travel expenses from Roche or others.

Source: Bravo J et al on behalf of the GABRIELL Study Group/Investigators. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: The phase II GABRIELL study. Leuk Lymphoma. 2023;64(5):913-926 (May 31). doi: 10.1080/10428194.2023.2216327

Key clinical point: The combination of obinutuzumab and bendamustine is a potent treatment option with a manageable safety profile for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Major finding: At a median follow-up of 33.4 months, the median progression-free survival was 26.0 (95% CI 20.3-31.7) months and the median overall survival was not reached. The overall response rate was 78.6%, with 28.6% of patients achieving complete response. The grade ≥3 adverse event (AE) rate was 76.4%, with neutropenia (58.3%), thrombocytopenia (26.4%), and febrile neutropenia (11.1%) being the most common grade ≥3 AE.

Study details: Findings are from the multicenter, phase 2 GABRIELL study that included 72 adult patients with relapsed or refractory CLL who received ≤6 cycles of obinutuzumab plus bendamustine.

Disclosures: This study was funded by Roche Farma SA. Some authors declared serving as advisory board or speaker bureau members with or without honoraria and receiving research support or attendance fees and travel expenses from Roche or others.

Source: Bravo J et al on behalf of the GABRIELL Study Group/Investigators. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: The phase II GABRIELL study. Leuk Lymphoma. 2023;64(5):913-926 (May 31). doi: 10.1080/10428194.2023.2216327

Key clinical point: The combination of obinutuzumab and bendamustine is a potent treatment option with a manageable safety profile for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Major finding: At a median follow-up of 33.4 months, the median progression-free survival was 26.0 (95% CI 20.3-31.7) months and the median overall survival was not reached. The overall response rate was 78.6%, with 28.6% of patients achieving complete response. The grade ≥3 adverse event (AE) rate was 76.4%, with neutropenia (58.3%), thrombocytopenia (26.4%), and febrile neutropenia (11.1%) being the most common grade ≥3 AE.

Study details: Findings are from the multicenter, phase 2 GABRIELL study that included 72 adult patients with relapsed or refractory CLL who received ≤6 cycles of obinutuzumab plus bendamustine.

Disclosures: This study was funded by Roche Farma SA. Some authors declared serving as advisory board or speaker bureau members with or without honoraria and receiving research support or attendance fees and travel expenses from Roche or others.

Source: Bravo J et al on behalf of the GABRIELL Study Group/Investigators. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: The phase II GABRIELL study. Leuk Lymphoma. 2023;64(5):913-926 (May 31). doi: 10.1080/10428194.2023.2216327

Key clinical point: Compared with chemoimmunotherapy (CIT), Bruton tyrosine kinase inhibitor (BTKi) therapy combined with anti-CD20 antibody therapy improves clinical outcomes in patients with treatment-naive chronic lymphocytic leukemia (CLL) without causing increased toxicity.

Major finding: Patients receiving BTKi+anti-CD20 antibody vs CIT had significantly prolonged progression-free survival (hazard ratio 0.25; 95% CI 0.15-0.42) and higher objective response rates (risk ratio [RR] 1.16; 95% CI 1.13-1.20) and a comparable risk for grade ≥3 adverse events (RR 1.04; 95% CI 0.92-1.17).

Study details: The data come from a meta-analysis of four randomized controlled trials involving 1479 patients with treatment-naive CLL who had been randomized to receive CIT or BTKi+anti-CD20 antibody therapy.

Disclosures: This study was partly supported by the Ministry of Science and Technology, Taiwan, and Taipei Medical University, Taiwan. The authors declared no conflicts of interest.

Source: Nguyen TT et al. Efficacy and safety of Bruton tyrosine kinase inhibitor plus anti-CD20 antibody therapy compared with chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized controlled trials. J Immunother. 2023 (May 23). doi: 10.1097/CJI.0000000000000471

Key clinical point: Compared with chemoimmunotherapy (CIT), Bruton tyrosine kinase inhibitor (BTKi) therapy combined with anti-CD20 antibody therapy improves clinical outcomes in patients with treatment-naive chronic lymphocytic leukemia (CLL) without causing increased toxicity.

Major finding: Patients receiving BTKi+anti-CD20 antibody vs CIT had significantly prolonged progression-free survival (hazard ratio 0.25; 95% CI 0.15-0.42) and higher objective response rates (risk ratio [RR] 1.16; 95% CI 1.13-1.20) and a comparable risk for grade ≥3 adverse events (RR 1.04; 95% CI 0.92-1.17).

Study details: The data come from a meta-analysis of four randomized controlled trials involving 1479 patients with treatment-naive CLL who had been randomized to receive CIT or BTKi+anti-CD20 antibody therapy.

Disclosures: This study was partly supported by the Ministry of Science and Technology, Taiwan, and Taipei Medical University, Taiwan. The authors declared no conflicts of interest.

Source: Nguyen TT et al. Efficacy and safety of Bruton tyrosine kinase inhibitor plus anti-CD20 antibody therapy compared with chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized controlled trials. J Immunother. 2023 (May 23). doi: 10.1097/CJI.0000000000000471

Key clinical point: Compared with chemoimmunotherapy (CIT), Bruton tyrosine kinase inhibitor (BTKi) therapy combined with anti-CD20 antibody therapy improves clinical outcomes in patients with treatment-naive chronic lymphocytic leukemia (CLL) without causing increased toxicity.

Major finding: Patients receiving BTKi+anti-CD20 antibody vs CIT had significantly prolonged progression-free survival (hazard ratio 0.25; 95% CI 0.15-0.42) and higher objective response rates (risk ratio [RR] 1.16; 95% CI 1.13-1.20) and a comparable risk for grade ≥3 adverse events (RR 1.04; 95% CI 0.92-1.17).

Study details: The data come from a meta-analysis of four randomized controlled trials involving 1479 patients with treatment-naive CLL who had been randomized to receive CIT or BTKi+anti-CD20 antibody therapy.

Disclosures: This study was partly supported by the Ministry of Science and Technology, Taiwan, and Taipei Medical University, Taiwan. The authors declared no conflicts of interest.

Source: Nguyen TT et al. Efficacy and safety of Bruton tyrosine kinase inhibitor plus anti-CD20 antibody therapy compared with chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized controlled trials. J Immunother. 2023 (May 23). doi: 10.1097/CJI.0000000000000471

Key clinical point: High-dose rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-High-CHOP)/cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER) followed by high-dose chemotherapy (HDC) with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED), and autologous peripheral blood stem cell transplantation (auto-PBSCT) provided favorable long-term survival outcomes in younger patients with untreated advanced mantle cell lymphoma (MCL).

Major finding: At 6-year median follow-up, the 5- and 8-year progression-free survival rates were 52.3% (95% CI 36.7%-65.7%) and 17.1% (95% CI 5.2%-34.7%), respectively, and the overall survival rates were 75.0% (95% CI 59.4%-85.3%) and 69.0% (95% CI 52.3%-80.9%), respectively. The incidence of secondary malignancies (11.1%) and continuous relapses was high.

Study details: This final analysis of the JCOG0406 study included 45 patients age ≤ 65 years with untreated advanced MCL who received R-High-CHOP/CHASER followed by HDC with LEED and auto-PBSCT.

Disclosures: This study was supported by Health and Labour Sciences Research Grants (Japan) and others. S Nakamura declared being an Editorial Board Member of Cancer Science. Some authors reported ties with various organizations.

Source: Ogura M et al. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406. Cancer Sci. 2023 (May 26). doi: 10.1111/cas.15849

Key clinical point: High-dose rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-High-CHOP)/cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER) followed by high-dose chemotherapy (HDC) with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED), and autologous peripheral blood stem cell transplantation (auto-PBSCT) provided favorable long-term survival outcomes in younger patients with untreated advanced mantle cell lymphoma (MCL).

Major finding: At 6-year median follow-up, the 5- and 8-year progression-free survival rates were 52.3% (95% CI 36.7%-65.7%) and 17.1% (95% CI 5.2%-34.7%), respectively, and the overall survival rates were 75.0% (95% CI 59.4%-85.3%) and 69.0% (95% CI 52.3%-80.9%), respectively. The incidence of secondary malignancies (11.1%) and continuous relapses was high.

Study details: This final analysis of the JCOG0406 study included 45 patients age ≤ 65 years with untreated advanced MCL who received R-High-CHOP/CHASER followed by HDC with LEED and auto-PBSCT.

Disclosures: This study was supported by Health and Labour Sciences Research Grants (Japan) and others. S Nakamura declared being an Editorial Board Member of Cancer Science. Some authors reported ties with various organizations.

Source: Ogura M et al. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406. Cancer Sci. 2023 (May 26). doi: 10.1111/cas.15849

Key clinical point: High-dose rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-High-CHOP)/cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER) followed by high-dose chemotherapy (HDC) with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED), and autologous peripheral blood stem cell transplantation (auto-PBSCT) provided favorable long-term survival outcomes in younger patients with untreated advanced mantle cell lymphoma (MCL).

Major finding: At 6-year median follow-up, the 5- and 8-year progression-free survival rates were 52.3% (95% CI 36.7%-65.7%) and 17.1% (95% CI 5.2%-34.7%), respectively, and the overall survival rates were 75.0% (95% CI 59.4%-85.3%) and 69.0% (95% CI 52.3%-80.9%), respectively. The incidence of secondary malignancies (11.1%) and continuous relapses was high.

Study details: This final analysis of the JCOG0406 study included 45 patients age ≤ 65 years with untreated advanced MCL who received R-High-CHOP/CHASER followed by HDC with LEED and auto-PBSCT.

Disclosures: This study was supported by Health and Labour Sciences Research Grants (Japan) and others. S Nakamura declared being an Editorial Board Member of Cancer Science. Some authors reported ties with various organizations.

Source: Ogura M et al. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406. Cancer Sci. 2023 (May 26). doi: 10.1111/cas.15849

Key clinical point: Compared with polatuzumab vedotin+bendamustine+rituximab (pola-BR) and rituximab+lenalidomide (R2), tafasitamab+lenalidomide provided a significant survival benefit in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Major finding: A significant overall survival (OS) benefit was observed with tafasitamab+lenalidomide vs pola-BR (hazard ratio [HR] 0.441; P = .034) and R2 (HR 0.435; P = .012). However, the OS was similar between the tafasitamab+lenalidomide and CD19-chimeric antigen receptor T-cell groups (CAR-T; HR 0.953; P = .892).

Study details: This expanded analysis of the RE-MIND2 study of propensity score-matched transplant-ineligible patients with R/R DLBCL treated with ≥2 systemic therapies who received tafasitamab+lenalidomide in the L-MIND trial and those who received pola-BR (24 pairs), R2 (33 pairs), or CAR-T (37 pairs) from an observational cohort.

Disclosures: This study was sponsored by MorphoSys AG. Some authors declared serving as consultants, advisory board members, or speakers and receiving research funding, honoraria, or travel support from MorphoSys and others. Four authors declared being employees of or holding equities in MorphoSys.

Source: Nowakowski GS et al. RE-MIND2: Comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma. Ann Hematol. 2023;102:1773-1787 (May 12). doi: 10.1007/s00277-023-05196-4

Key clinical point: Compared with polatuzumab vedotin+bendamustine+rituximab (pola-BR) and rituximab+lenalidomide (R2), tafasitamab+lenalidomide provided a significant survival benefit in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Major finding: A significant overall survival (OS) benefit was observed with tafasitamab+lenalidomide vs pola-BR (hazard ratio [HR] 0.441; P = .034) and R2 (HR 0.435; P = .012). However, the OS was similar between the tafasitamab+lenalidomide and CD19-chimeric antigen receptor T-cell groups (CAR-T; HR 0.953; P = .892).

Study details: This expanded analysis of the RE-MIND2 study of propensity score-matched transplant-ineligible patients with R/R DLBCL treated with ≥2 systemic therapies who received tafasitamab+lenalidomide in the L-MIND trial and those who received pola-BR (24 pairs), R2 (33 pairs), or CAR-T (37 pairs) from an observational cohort.

Disclosures: This study was sponsored by MorphoSys AG. Some authors declared serving as consultants, advisory board members, or speakers and receiving research funding, honoraria, or travel support from MorphoSys and others. Four authors declared being employees of or holding equities in MorphoSys.

Source: Nowakowski GS et al. RE-MIND2: Comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma. Ann Hematol. 2023;102:1773-1787 (May 12). doi: 10.1007/s00277-023-05196-4

Key clinical point: Compared with polatuzumab vedotin+bendamustine+rituximab (pola-BR) and rituximab+lenalidomide (R2), tafasitamab+lenalidomide provided a significant survival benefit in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Major finding: A significant overall survival (OS) benefit was observed with tafasitamab+lenalidomide vs pola-BR (hazard ratio [HR] 0.441; P = .034) and R2 (HR 0.435; P = .012). However, the OS was similar between the tafasitamab+lenalidomide and CD19-chimeric antigen receptor T-cell groups (CAR-T; HR 0.953; P = .892).

Study details: This expanded analysis of the RE-MIND2 study of propensity score-matched transplant-ineligible patients with R/R DLBCL treated with ≥2 systemic therapies who received tafasitamab+lenalidomide in the L-MIND trial and those who received pola-BR (24 pairs), R2 (33 pairs), or CAR-T (37 pairs) from an observational cohort.

Disclosures: This study was sponsored by MorphoSys AG. Some authors declared serving as consultants, advisory board members, or speakers and receiving research funding, honoraria, or travel support from MorphoSys and others. Four authors declared being employees of or holding equities in MorphoSys.

Source: Nowakowski GS et al. RE-MIND2: Comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma. Ann Hematol. 2023;102:1773-1787 (May 12). doi: 10.1007/s00277-023-05196-4

Key clinical point: The rituximab, bendamustine, and low-dose cytarabine (R-BAC) regimen, not succeeded by maintenance therapy, induces long-term responses in previously untreated elderly patients with mantle cell lymphoma (MCL).

Major finding: After a median follow-up of 86 months, the median overall survival (OS) and progression-free survival (PFS) were not reached; the 7-year PFS and OS rates were 55% (95% CI 41%-67%) and 63% (95% CI 49%-74%), respectively. The 7-year duration of response rate among the 52 responding patients was 59% (95% CI 44%-71%). No signal of late toxicity was reported.

Study details: Findings are from a long-term analysis of the FIL-RBAC500 trial that included 57 previously untreated elderly patients with MCL who received the R-BAC regimen.

Disclosures: This study was supported by Progetto di Ricerca Sanitaria Finalizzata (Italy) grants and other sources. Some authors declared serving as advisory board members or consultants and receiving research funding, speaker honoraria, or travel expenses and accommodations from various sources.

Source: Tisi MC et al. Long term follow-up of rituximab plus bendamustine and cytarabine (R-BAC) in elderly patients with newly diagnosed MCL. Blood Adv. 2023 (May 12). doi: 10.1182/bloodadvances.2023009744

Key clinical point: The rituximab, bendamustine, and low-dose cytarabine (R-BAC) regimen, not succeeded by maintenance therapy, induces long-term responses in previously untreated elderly patients with mantle cell lymphoma (MCL).

Major finding: After a median follow-up of 86 months, the median overall survival (OS) and progression-free survival (PFS) were not reached; the 7-year PFS and OS rates were 55% (95% CI 41%-67%) and 63% (95% CI 49%-74%), respectively. The 7-year duration of response rate among the 52 responding patients was 59% (95% CI 44%-71%). No signal of late toxicity was reported.

Study details: Findings are from a long-term analysis of the FIL-RBAC500 trial that included 57 previously untreated elderly patients with MCL who received the R-BAC regimen.

Disclosures: This study was supported by Progetto di Ricerca Sanitaria Finalizzata (Italy) grants and other sources. Some authors declared serving as advisory board members or consultants and receiving research funding, speaker honoraria, or travel expenses and accommodations from various sources.

Source: Tisi MC et al. Long term follow-up of rituximab plus bendamustine and cytarabine (R-BAC) in elderly patients with newly diagnosed MCL. Blood Adv. 2023 (May 12). doi: 10.1182/bloodadvances.2023009744

Key clinical point: The rituximab, bendamustine, and low-dose cytarabine (R-BAC) regimen, not succeeded by maintenance therapy, induces long-term responses in previously untreated elderly patients with mantle cell lymphoma (MCL).

Major finding: After a median follow-up of 86 months, the median overall survival (OS) and progression-free survival (PFS) were not reached; the 7-year PFS and OS rates were 55% (95% CI 41%-67%) and 63% (95% CI 49%-74%), respectively. The 7-year duration of response rate among the 52 responding patients was 59% (95% CI 44%-71%). No signal of late toxicity was reported.

Study details: Findings are from a long-term analysis of the FIL-RBAC500 trial that included 57 previously untreated elderly patients with MCL who received the R-BAC regimen.

Disclosures: This study was supported by Progetto di Ricerca Sanitaria Finalizzata (Italy) grants and other sources. Some authors declared serving as advisory board members or consultants and receiving research funding, speaker honoraria, or travel expenses and accommodations from various sources.

Source: Tisi MC et al. Long term follow-up of rituximab plus bendamustine and cytarabine (R-BAC) in elderly patients with newly diagnosed MCL. Blood Adv. 2023 (May 12). doi: 10.1182/bloodadvances.2023009744

Key clinical point: First-line ibrutinib+venetoclax led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) regardless of high-risk genomic features generally associated with poor outcomes.

Major finding: Overall response and 36-month overall survival rates were >95% regardless of high-risk features. Patients with and without high-risk features had similar complete response (61% [95% CI 53%-70%] and 53% [95% CI 41%-65%], respectively) and 36-month progression-free survival (88% [95% CI 81%-93%] and 92% [95% CI 82%-97%], respectively) rates.

Study details: This post hoc analysis of the CAPTIVATE trial analyzed the pooled data of 195 patients with previously untreated CLL/SLL and known status of high-risk features [del(17p), TP53 mutation, and unmutated immunoglobulin heavy chain] treated with fixed-duration ibrutinib+venetoclax, of which 129 had ≥1 high-risk feature.

Disclosures: This study was funded by Pharmacyclics LLC, an AbbVie Company. Some authors declared receiving grants, personal fees, or other support from Pharmacyclics, AbbVie, or others. Two authors declared being employees of Pharmacyclics or AbbVie or having stock or other ownership interests in AbbVie.

Source: Allan JN et al. Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: Phase II CAPTIVATE study in first-line chronic lymphocytic leukemia. Clin Cancer Res. 2023 (Jun 7). doi: 10.1158/1078-0432.CCR-22-2779

Key clinical point: First-line ibrutinib+venetoclax led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) regardless of high-risk genomic features generally associated with poor outcomes.

Major finding: Overall response and 36-month overall survival rates were >95% regardless of high-risk features. Patients with and without high-risk features had similar complete response (61% [95% CI 53%-70%] and 53% [95% CI 41%-65%], respectively) and 36-month progression-free survival (88% [95% CI 81%-93%] and 92% [95% CI 82%-97%], respectively) rates.

Study details: This post hoc analysis of the CAPTIVATE trial analyzed the pooled data of 195 patients with previously untreated CLL/SLL and known status of high-risk features [del(17p), TP53 mutation, and unmutated immunoglobulin heavy chain] treated with fixed-duration ibrutinib+venetoclax, of which 129 had ≥1 high-risk feature.

Disclosures: This study was funded by Pharmacyclics LLC, an AbbVie Company. Some authors declared receiving grants, personal fees, or other support from Pharmacyclics, AbbVie, or others. Two authors declared being employees of Pharmacyclics or AbbVie or having stock or other ownership interests in AbbVie.

Source: Allan JN et al. Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: Phase II CAPTIVATE study in first-line chronic lymphocytic leukemia. Clin Cancer Res. 2023 (Jun 7). doi: 10.1158/1078-0432.CCR-22-2779

Key clinical point: First-line ibrutinib+venetoclax led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) regardless of high-risk genomic features generally associated with poor outcomes.

Major finding: Overall response and 36-month overall survival rates were >95% regardless of high-risk features. Patients with and without high-risk features had similar complete response (61% [95% CI 53%-70%] and 53% [95% CI 41%-65%], respectively) and 36-month progression-free survival (88% [95% CI 81%-93%] and 92% [95% CI 82%-97%], respectively) rates.

Study details: This post hoc analysis of the CAPTIVATE trial analyzed the pooled data of 195 patients with previously untreated CLL/SLL and known status of high-risk features [del(17p), TP53 mutation, and unmutated immunoglobulin heavy chain] treated with fixed-duration ibrutinib+venetoclax, of which 129 had ≥1 high-risk feature.

Disclosures: This study was funded by Pharmacyclics LLC, an AbbVie Company. Some authors declared receiving grants, personal fees, or other support from Pharmacyclics, AbbVie, or others. Two authors declared being employees of Pharmacyclics or AbbVie or having stock or other ownership interests in AbbVie.

Source: Allan JN et al. Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: Phase II CAPTIVATE study in first-line chronic lymphocytic leukemia. Clin Cancer Res. 2023 (Jun 7). doi: 10.1158/1078-0432.CCR-22-2779

Key clinical point: The preexistence of depression, anxiety, or both is associated with shorter survival in older patients with diffuse large B-cell lymphoma (DLBCL).

Major finding: At a median follow-up of 2.0 years, patients with depression, anxiety, or both vs without any mental disorder had significantly lower 5-year overall survival rates (27.0% vs 37.4%; hazard ratio [HR] 1.37; 95% CI 1.29-1.44), with those with preexisting depression vs without any mental disorder having the worst rate (23.4% vs 38.0%; HR 1.37; P < .0001).

Study details: This retrospective cohort study analyzed the data of 13,244 patients age ≥ 67 years with DLBCL from the Surveillance, Epidemiology, and End Results-Medicare (SEER) registry, of which 2094 had depression, anxiety, or both at the time of their DLBCL diagnosis.

Disclosures: This study was funded by the American Society of Hematology and others. Some authors declared participating on Data Safety Monitoring or Advisory Boards or receiving financial support, royalties or licenses, or payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from various organizations.

Source: Kuczmarski TM et al. Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: A population-based study. Lancet Haematol. 2023 (Jun 1). doi: 10.1016/S2352-3026(23)00094-7

Key clinical point: The preexistence of depression, anxiety, or both is associated with shorter survival in older patients with diffuse large B-cell lymphoma (DLBCL).

Major finding: At a median follow-up of 2.0 years, patients with depression, anxiety, or both vs without any mental disorder had significantly lower 5-year overall survival rates (27.0% vs 37.4%; hazard ratio [HR] 1.37; 95% CI 1.29-1.44), with those with preexisting depression vs without any mental disorder having the worst rate (23.4% vs 38.0%; HR 1.37; P < .0001).

Study details: This retrospective cohort study analyzed the data of 13,244 patients age ≥ 67 years with DLBCL from the Surveillance, Epidemiology, and End Results-Medicare (SEER) registry, of which 2094 had depression, anxiety, or both at the time of their DLBCL diagnosis.

Disclosures: This study was funded by the American Society of Hematology and others. Some authors declared participating on Data Safety Monitoring or Advisory Boards or receiving financial support, royalties or licenses, or payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from various organizations.

Source: Kuczmarski TM et al. Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: A population-based study. Lancet Haematol. 2023 (Jun 1). doi: 10.1016/S2352-3026(23)00094-7

Key clinical point: The preexistence of depression, anxiety, or both is associated with shorter survival in older patients with diffuse large B-cell lymphoma (DLBCL).

Major finding: At a median follow-up of 2.0 years, patients with depression, anxiety, or both vs without any mental disorder had significantly lower 5-year overall survival rates (27.0% vs 37.4%; hazard ratio [HR] 1.37; 95% CI 1.29-1.44), with those with preexisting depression vs without any mental disorder having the worst rate (23.4% vs 38.0%; HR 1.37; P < .0001).

Study details: This retrospective cohort study analyzed the data of 13,244 patients age ≥ 67 years with DLBCL from the Surveillance, Epidemiology, and End Results-Medicare (SEER) registry, of which 2094 had depression, anxiety, or both at the time of their DLBCL diagnosis.

Disclosures: This study was funded by the American Society of Hematology and others. Some authors declared participating on Data Safety Monitoring or Advisory Boards or receiving financial support, royalties or licenses, or payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from various organizations.

Source: Kuczmarski TM et al. Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: A population-based study. Lancet Haematol. 2023 (Jun 1). doi: 10.1016/S2352-3026(23)00094-7

Key clinical point: Compared with the current standard-of-care chemoimmunotherapy, second-line axicabtagene ciloleucel (axi-cel) significantly prolongs the overall survival of patients with early relapsed or refractory large B-cell lymphoma (LBCL).

Major finding: At a median follow-up of 47.2 months, patients receiving axi-cel vs standard care had a significantly longer median overall survival (not reached vs 31.1 months; hazard ratio 0.73; P = .03) and an absolute improvement in overall survival (8.6 percentage points at 4 years). No new treatment-related deaths were reported since the primary event-free survival analysis.

Study details: This primary overall survival analysis of the phase 3 ZUMA-7 trial included 359 adults with LBCL (refractory to or relapsed after first-line treatment) who were randomly assigned to receive axi-cel (n = 180) or standard care (n = 179).

Disclosures: This study was funded by Kite Pharma. Some authors, including the lead author, declared serving as advisory board members, consultants, or speakers for; receiving research support, speaker fees, travel expenses, or honoraria from; or owning stock or stock options in various sources, including Kite.

Source: Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023 (Jun 5). doi: 10.1056/NEJMoa2301665

Key clinical point: Compared with the current standard-of-care chemoimmunotherapy, second-line axicabtagene ciloleucel (axi-cel) significantly prolongs the overall survival of patients with early relapsed or refractory large B-cell lymphoma (LBCL).

Major finding: At a median follow-up of 47.2 months, patients receiving axi-cel vs standard care had a significantly longer median overall survival (not reached vs 31.1 months; hazard ratio 0.73; P = .03) and an absolute improvement in overall survival (8.6 percentage points at 4 years). No new treatment-related deaths were reported since the primary event-free survival analysis.

Study details: This primary overall survival analysis of the phase 3 ZUMA-7 trial included 359 adults with LBCL (refractory to or relapsed after first-line treatment) who were randomly assigned to receive axi-cel (n = 180) or standard care (n = 179).

Disclosures: This study was funded by Kite Pharma. Some authors, including the lead author, declared serving as advisory board members, consultants, or speakers for; receiving research support, speaker fees, travel expenses, or honoraria from; or owning stock or stock options in various sources, including Kite.

Source: Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023 (Jun 5). doi: 10.1056/NEJMoa2301665

Key clinical point: Compared with the current standard-of-care chemoimmunotherapy, second-line axicabtagene ciloleucel (axi-cel) significantly prolongs the overall survival of patients with early relapsed or refractory large B-cell lymphoma (LBCL).

Major finding: At a median follow-up of 47.2 months, patients receiving axi-cel vs standard care had a significantly longer median overall survival (not reached vs 31.1 months; hazard ratio 0.73; P = .03) and an absolute improvement in overall survival (8.6 percentage points at 4 years). No new treatment-related deaths were reported since the primary event-free survival analysis.

Study details: This primary overall survival analysis of the phase 3 ZUMA-7 trial included 359 adults with LBCL (refractory to or relapsed after first-line treatment) who were randomly assigned to receive axi-cel (n = 180) or standard care (n = 179).

Disclosures: This study was funded by Kite Pharma. Some authors, including the lead author, declared serving as advisory board members, consultants, or speakers for; receiving research support, speaker fees, travel expenses, or honoraria from; or owning stock or stock options in various sources, including Kite.

Source: Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023 (Jun 5). doi: 10.1056/NEJMoa2301665

Key clinical point: Pirtobrutinib demonstrated durable efficacy and a favorable safety profile in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated relapsed or refractory mantle cell lymphoma (MCL).

Major finding: The overall response rate was 57.8% (95% CI 46.9%-68.1%), with the complete response rate being 20.0%. At a median follow-up of 12 months, the median duration of response was 21.6 (95% CI 7.5-not reached) months. Grade ≥3 treatment-related adverse events were not frequent, with neutropenia (8.5%) being the most common.

Study details: This multicenter phase 1/2 BRUIN trial included 90 cBTKi pretreated patients with relapsed or refractory MCL in the primary efficacy cohort who received 25-300 mg and 200 mg pirtobrutinib once daily orally in the phases 1 and 2 of the trial, respectively.

Disclosures: This study was sponsored by Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company. Some authors reported ties with Eli Lilly and others. Seven authors declared being employees of or stockholders in Eli Lilly.

Source: Wang ML et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma. J Clin Oncol. 2023 (May 16). doi: 10.1200/JCO.23.00562

Key clinical point: Pirtobrutinib demonstrated durable efficacy and a favorable safety profile in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated relapsed or refractory mantle cell lymphoma (MCL).

Major finding: The overall response rate was 57.8% (95% CI 46.9%-68.1%), with the complete response rate being 20.0%. At a median follow-up of 12 months, the median duration of response was 21.6 (95% CI 7.5-not reached) months. Grade ≥3 treatment-related adverse events were not frequent, with neutropenia (8.5%) being the most common.

Study details: This multicenter phase 1/2 BRUIN trial included 90 cBTKi pretreated patients with relapsed or refractory MCL in the primary efficacy cohort who received 25-300 mg and 200 mg pirtobrutinib once daily orally in the phases 1 and 2 of the trial, respectively.

Disclosures: This study was sponsored by Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company. Some authors reported ties with Eli Lilly and others. Seven authors declared being employees of or stockholders in Eli Lilly.

Source: Wang ML et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma. J Clin Oncol. 2023 (May 16). doi: 10.1200/JCO.23.00562

Key clinical point: Pirtobrutinib demonstrated durable efficacy and a favorable safety profile in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated relapsed or refractory mantle cell lymphoma (MCL).

Major finding: The overall response rate was 57.8% (95% CI 46.9%-68.1%), with the complete response rate being 20.0%. At a median follow-up of 12 months, the median duration of response was 21.6 (95% CI 7.5-not reached) months. Grade ≥3 treatment-related adverse events were not frequent, with neutropenia (8.5%) being the most common.

Study details: This multicenter phase 1/2 BRUIN trial included 90 cBTKi pretreated patients with relapsed or refractory MCL in the primary efficacy cohort who received 25-300 mg and 200 mg pirtobrutinib once daily orally in the phases 1 and 2 of the trial, respectively.

Disclosures: This study was sponsored by Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company. Some authors reported ties with Eli Lilly and others. Seven authors declared being employees of or stockholders in Eli Lilly.

Source: Wang ML et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma. J Clin Oncol. 2023 (May 16). doi: 10.1200/JCO.23.00562